^
BIOMARKER:

PTEN deletion

i
Other names: PTEN, Phosphatase and tensin homolog, Mutated In Multiple Advanced Cancers 1, Phosphatase And Tensin Homolog, Phosphatidylinositol 3,4,5-Trisphosphate 3-Phosphatase And Dual-Specificity Protein Phosphatase PTEN, MMAC1, TEP1, MMAC1 Phosphatase And Tensin Homolog Deleted On Chromosome 10, Mitochondrial Phosphatase And Tensin Protein Alpha, Phosphatase And Tensin-Like Protein, Protein Tyrosine Phosphatase, Mitochondrial PTENalpha, PTENbeta, PTEN1, CWS1, GLM2, MHAM
Entrez ID:
Related biomarkers:
PTEN deletion
Prostate Cancer
RG7440 + AST-2970 + prednisolone
Sensitive: B - Late Trials
PTEN deletion
HER2 Positive Breast Cancer
everolimus
Sensitive: B - Late Trials
PTEN deletion
Prostate Cancer
RG7440
Sensitive: B - Late Trials
PTEN deletion
Solid Tumor
avelumab
Sensitive: C3 – Early Trials
PTEN deletion
Gastric Cancer
trastuzumab
Resistant: C3 – Early Trials
PTEN deletion
Gastric Cancer
lapatinib
Resistant: C3 – Early Trials
PTEN deletion
Breast Cancer
bevacizumab + temsirolimus
Sensitive: C3 – Early Trials
PTEN deletion
Prostate Cancer
GSK2636771
Sensitive: C3 – Early Trials
PTEN deletion
CRC
cetuximab
Resistant: C3 – Early Trials
PTEN deletion
Melanoma
Immunotherapy
Resistant: C3 – Early Trials
PTEN deletion
Melanoma
vemurafenib
Sensitive: C3 – Early Trials
PTEN deletion
Endometrial Cancer
olaparib
Sensitive: C3 – Early Trials
PTEN deletion
CRC
panitumumab
Resistant: C3 – Early Trials
PTEN deletion
CRC
bevacizumab + nanoparticle albumin-bound rapamycin
Sensitive: C3 – Early Trials
PTEN deletion
Prostate Cancer
everolimus
Sensitive: C3 – Early Trials
PTEN deletion
HER2 Positive Breast Cancer
trastuzumab
Resistant: C3 – Early Trials
PTEN deletion
Prostate Cancer
abiraterone acetate
Resistant: C3 – Early Trials
PTEN deletion
Prostate Cancer
enzalutamide capsule
Resistant: C3 – Early Trials
PTEN deletion
Prostate Cancer
darolutamide
Sensitive: C3 – Early Trials
PTEN deletion
Prostate Cancer
apalutamide
Sensitive: C3 – Early Trials
PTEN deletion
Prostate Cancer
enzalutamide capsule + CC-115
Sensitive: C3 – Early Trials
PTEN deletion
RCC
CB-228
Resistant: C3 – Early Trials
PTEN deletion
Prostate Cancer
pembrolizumab + GSK2636771
Sensitive: C3 – Early Trials
PTEN deletion
Chordoma
PDGFR inhibitor
Resistant: C4 – Case Studies
PTEN deletion
Chordoma
PDGFR inhibitor + HDAC inhibitor
Sensitive: C4 – Case Studies
PTEN deletion
Breast Cancer
alpelisib
Resistant: C4 – Case Studies
PTEN deletion
Melanoma
dabrafenib
Sensitive: C4 – Case Studies
PTEN deletion
Prostate Cancer
ATM kinase inhibitor
Sensitive: D – Preclinical
PTEN deletion
Gastric Cancer
AZD5363
Sensitive: D – Preclinical
PTEN deletion
Triple Negative Breast Cancer
AZD8186
Sensitive: D – Preclinical
PTEN deletion
HER2 Positive Breast Cancer
MEN1611
Sensitive: D – Preclinical
PTEN deletion
GBM
MLN4924
Resistant: D – Preclinical
PTEN deletion
Glioma
MLN4924
Resistant: D – Preclinical
PTEN deletion
Prostate Cancer
apalutamide + AZD4635
Sensitive: D – Preclinical
PTEN deletion
Prostate Cancer
AZD4635
Sensitive: D – Preclinical
PTEN deletion
NSCLC
GDC-0941
Sensitive: D – Preclinical
PTEN deletion
Melanoma
GSK2636771 + ENUM004
Sensitive: D – Preclinical
PTEN deletion
Ovarian Cancer
AVTX-006
Sensitive: D – Preclinical
PTEN deletion
Ovarian Cancer
PD-0325901 + PF-04691502
Sensitive: D – Preclinical
PTEN deletion
Ovarian Cancer
PF-04691502
Sensitive: D – Preclinical
PTEN deletion
LUAD
selumetinib + MK-2206
Sensitive: D – Preclinical
PTEN deletion
NSCLC
erlotinib
Resistant: D – Preclinical
PTEN deletion
Prostate Cancer
MEN1611
Sensitive: D – Preclinical
PTEN deletion
Prostate Cancer
enzalutamide capsule + AZD5363
Sensitive: D – Preclinical
PTEN deletion
Melanoma
MK-2206
Sensitive: D – Preclinical
PTEN deletion
Melanoma
CI-1040
Sensitive: D – Preclinical
PTEN deletion
Gastric Cancer
MEN1611
Sensitive: D – Preclinical
PTEN deletion
Prostate Cancer
mTORC1 inhibitor
Sensitive: D – Preclinical
PTEN deletion
Breast Cancer
MLN4924
Resistant: D – Preclinical
PTEN deletion
Prostate Cancer
AZD5363 + AST-2970
Sensitive: D – Preclinical